Clinical Trials
23 trialsNCT05032820 2026-05-19
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
Phase 2 Completed
NCT03246906 2026-05-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT03030248 2026-04-15
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Medical College of Wisconsin
Phase 2 Completed
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03159702 2026-01-27
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT00988013 2021-06-14
IM-TMI
University of Illinois at Chicago
Phase NA Completed
NCT01670097 2021-02-17
Dexamethasone Dyspnea Study
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01010217 2020-03-25
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00213239 2019-12-02
A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
The Hospital for Sick Children
Phase 1/2 Completed
NCT03195010 2019-10-21
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02095951 2018-12-19
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Children's Hospital of Michigan
Phase 4 Completed
NCT01924169 2018-09-20
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01220297 2017-06-05
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Stanford University
Phase 2 Terminated
NCT01191749 2017-05-09
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00800839 2016-09-19
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01359254 2015-04-30
Cord Blood Transplantation for Patients With Cancer
University of Chicago
Phase 2 Terminated
NCT00231309 2014-08-22
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Emory University
Phase NA Completed
NCT00977548 2013-09-16
Erlotinib Study for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01031498 2012-08-07
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00790452 2011-12-08
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00582894 2011-04-22
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
University of Oklahoma
Phase NA Completed